The Biopharmaceutical Company focused on the biology of healing, last week published new pre-clinical data supportive of ProMetic’s lead small molecule candidates anti-fibrotic capabilities, this time in the liver. In various NASH animal models (Non-alcoholic steatohepatitis) PBI-4050 demonstrated an anti-fibrotic effect. Encouragingly the anti-fibrotic effect has been successfully reproduced in human hepatic stellate cells (“HHSC”) during in vitro preclinical experiments. P
20 Apr 2016
The case for PBI 4050 strengthens
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The case for PBI 4050 strengthens
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
20 Apr 2016 -
Author:
Derren Nathan -
Pages:
7
The Biopharmaceutical Company focused on the biology of healing, last week published new pre-clinical data supportive of ProMetic’s lead small molecule candidates anti-fibrotic capabilities, this time in the liver. In various NASH animal models (Non-alcoholic steatohepatitis) PBI-4050 demonstrated an anti-fibrotic effect. Encouragingly the anti-fibrotic effect has been successfully reproduced in human hepatic stellate cells (“HHSC”) during in vitro preclinical experiments. P